Abeona Therapeutics Inc./$ABEO
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Abeona Therapeutics Inc.
Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company. The firm is focused on developing gene therapies and plasma-based products for life-threatening rare genetic diseases. Its clinical programs consist of pz-cel, an autologous, engineered cell therapy currently in development for recessive dystrophic epidermolysis bullosa (RDEB). The Company's development portfolio also features adeno-associated virus (AAV)-based gene therapies designed to treat unmet, medically needed ophthalmic diseases using the novel.
Ticker
$ABEO
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
136
ISIN
US00289Y2063
Website
ABEO Metrics
BasicAdvanced
$307M
-
-$0.95
1.55
-
Price and volume
Market cap
$307M
Beta
1.55
52-week high
$7.32
52-week low
$3.93
Average daily volume
1.3M
Financial strength
Current ratio
4.9
Quick ratio
4.77
Long term debt to equity
36.757
Total debt to equity
57.921
Interest coverage (TTM)
-16.36%
Profitability
EBITDA (TTM)
-67.561
Management effectiveness
Return on assets (TTM)
-49.95%
Return on equity (TTM)
-271.78%
Valuation
Price to book
7.1
Price to tangible book (TTM)
7.1
Price to free cash flow (TTM)
-4.444
Free cash flow yield (TTM)
-22.50%
Free cash flow per share (TTM)
-135.01%
Growth
Earnings per share change (TTM)
-70.38%
3-year earnings per share growth (CAGR)
-64.10%
10-year earnings per share growth (CAGR)
-37.87%
Bulls say / Bears say
The U.S. FDA approved Abeona's gene therapy, Zevaskyn (pz-cel), for treating recessive dystrophic epidermolysis bullosa (RDEB), marking the first cell-based gene therapy for this condition. (reuters.com)
Oppenheimer initiated coverage of Abeona Therapeutics with an 'Outperform' rating and a price target of $16.00, suggesting significant upside potential. (nasdaq.com)
Abeona reported a cash position of $98.1 million as of December 31, 2024, up from $52.6 million the previous year, indicating improved financial stability. (globenewswire.com)
StockNews.com downgraded Abeona Therapeutics to a 'Sell' rating, reflecting potential concerns about the company's prospects. (americanbankingnews.com)
Despite the FDA approval of Zevaskyn, the high treatment cost of $1.75 million per round may limit market adoption and revenue growth. (reuters.com)
Abeona reported a net loss of $63.7 million for the full year 2024, an increase from the $54.2 million loss in 2023, indicating ongoing financial challenges. (globenewswire.com)
Data summarised monthly by Lightyear AI. Last updated on 4 Jun 2025.
ABEO News
AllArticlesVideos
Abeona Therapeutics® Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·2 weeks ago
Abeona Therapeutics® to Present at the Jefferies Global Healthcare Conference
GlobeNewsWire·3 weeks ago
Abeona Therapeutics® Reports First Quarter 2025 Financial Results and Corporate Updates
GlobeNewsWire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Abeona Therapeutics Inc. stock?
Abeona Therapeutics Inc. (ABEO) has a market cap of $307M as of June 18, 2025.
What is the P/E ratio for Abeona Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Abeona Therapeutics Inc. (ABEO) stock is 0 as of June 18, 2025.
Does Abeona Therapeutics Inc. stock pay dividends?
No, Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders as of June 18, 2025.
When is the next Abeona Therapeutics Inc. dividend payment date?
Abeona Therapeutics Inc. (ABEO) stock does not pay dividends to its shareholders.
What is the beta indicator for Abeona Therapeutics Inc.?
Abeona Therapeutics Inc. (ABEO) has a beta rating of 1.55. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.